

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
27 May 2004 (27.05.2004)

PCT

(10) International Publication Number
WO 2004/043238 A2

(51) International Patent Classification⁷: **A61B** MI 48084 (US). CHRISTNER, Robert [US/US]; 2262 Parkwood Avenue, Toledo, OH 43620 (US).

(21) International Application Number: PCT/US2003/036120 (74) Agents: BENT, Stephen, A. et al.; Foley & Lardner, Washington Harbour, Suite 500, 3000 "K" Street, N.W., Washington, DC 20007-5101 (US).

(22) International Filing Date: 13 November 2003 (13.11.2003) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English (84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

(30) Priority Data: 60/426,096 14 November 2002 (14.11.2002) US

(71) Applicant (*for all designated States except US*): CIPHER-GEN BIOSYSTEMS, INC. [US/US]; 6611 Dumbarton Circle, Freemont, CA 94555 (US).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): BUHIMSCHI, Irina, A. [US/US]; 2728 Alisop Place, Apt. 309, Troy,

[Continued on next page]

(54) Title: BIOMARKERS FOR INTRO-AMNIOTIC INFLAMMATION



WO 2004/043238 A2



(57) Abstract: Biomarkers have been discovered that are capable of identifying intra-amniotic inflammation. A single biomarker or combination of biomarkers can be used to qualify the risk of preterm delivery in a patient, provided that at least one of the biomarkers is a calgranulin, preferably calgranulin A or C. The result is a rapid and reliable proteomic approach to identifying intra-amniotic inflammation. In particular, the concentrations of the biomarkers correlate with the magnitude of intra-amniotic inflammation and, hence, of preterm delivery.